ClinicalTrials.gg
Active, not recruitingNCT04781088Updated Oct 21, 2026Results posted

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2 interventional study of Lenvatinib and Paclitaxel in Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, sponsored by Floor Backes, MD. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Floor Backes, MD · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Updated Oct 21, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing lenvatinib in Endometrial Neoplasms — 4 open to participants now, 6 under way, none of them phase 3. lenvatinib · Endometrial Neoplasms.

Enrollment
7th of 15
38 · median 32
Started
2021
the only one that year
Phase 2
6 of 15
1 open now
Registered
8th of 15
by date
Lead sponsor
1 of 15
Floor Backes, MD

Among the 15 studies testing lenvatinib in Endometrial Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 8th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 15 studies testing lenvatinib in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing lenvatinib in Endometrial Neoplasms, or all of them as a file.
02

Study summary

This phase II clinical trial studies the effect of lenvatinib, pembrolizumab, and paclitaxel in treating patients with endometrial, epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). While all 3 study drugs are FDA approved, and 2-drug combinations have been studied, the 3- drug combination has not been studied yet. The investigators believe that the addition of pembrolizumab to weekly paclitaxel and lenvatinib (or weekly paclitaxel to pembrolizumab and lenvatinib) is highly effective and safe with manageable side effects in both recurrent endometrial and platinum resistant ovarian cancer. The purpose of this trial is to study how well lenvatinib, pembrolizumab, and weekly paclitaxel work together in women who have recurrent endometrial cancer and/or recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer, and what kind of side effects patients may experience.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine objective antitumor activity (complete and partial response) of lenvatinib, pembrolizumab, and weekly paclitaxel as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in recurrent endometrial and platinum resistant ovarian cancer.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability weekly paclitaxel, lenvatinib, and pembrolizumab in study patients.

II. To measure the progression free survival in the study population. III. To measure the overall survival in the study population.

EXPLORATORY OBJECTIVE:

I. To explore the baseline tumor genetic and microenvironment parameters predictive of clinical benefit or resistance to the treatment combination and potential mechanisms of resistance.

OUTLINE:

Beginning cycle 1 day 1, patients receive lenvatinib PO daily, pembrolizumab IV on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15, on a 21 day cycle in the absence of disease progression or unacceptable toxicity.

03

Conditions studied

  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Endometrial Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma

Keywords

  • endometrial cancer
  • ovarian cancer
  • platinum resistant
  • phase 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are at least 18 years of age on the day of signing will be enrolled in this study
  • Women with confirmed endometrial cancer, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (all histological subtypes)
  • Patients must have received prior treatment with a platinum containing regimen and may have received 1-3 prior regimens. Hormonal therapy and maintenance therapy (with bevacizumab or PARP inhibitor) does not count towards the number of prior treatments
  • Patients with ovarian, fallopian tube or primary peritoneal cancer must be platinum resistant (progression \< 6 months after completion of a platinum containing regimen) or not a candidate for further platinum treatment
  • Patients with and without mismatch repair deficiency are allowed
  • Prior /PD-L1 inhibitors are allowed as long as this was not the most recent regimen and treatment was not discontinued due to side effects/toxicity. Prior weekly paclitaxel is allowed as long as this was not the most recent regimen and treatment was not discontinued due to side effects/toxicity
  • Prior targeted therapy targeting angiogenesis is allowed as long as treatment was not discontinued due to side effects/toxicity
  • Have based on 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • Not a woman of (WOCBP) as defined OR
    • A WOCBP who agrees to follow the guidance during the treatment period and for at least 4 months (corresponding to time needed to eliminate any study treatment[s] MK and or any active comparator/combination) plus 30 days (a menstruation cycle) after the last dose of study treatment
  • The participant (or legally acceptable representative if applicable) provides written informed consent for the trial
  • Have provided sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.
  • Have an (ECOG) performance status of 0 to 1.
  • (ANC) >= 1500/uL (within 10 days prior to the start of study treatment)
  • >= 100 000/uL (within 10 days prior to the start of study treatment)
  • >= 9.0 g/dL or >= 5.6 mmol/L (within 10 days prior to the start of study treatment)

    • Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks
  • Creatinine =\< 1.5 x (ULN) OR measured or calculated ( [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN (within 10 days prior to the start of study treatment)

    • Creatinine clearance (CrCl) should be calculated per institutional standard
  • Total =\< 1.5 x ULN OR direct bilirubin =\< ULN for participants with total bilirubin levels > 1.5 x ULN (within 10 days prior to the start of study treatment)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =\< 2.5 x ULN (=\< 5 x ULN for participants with liver ) (within 10 days prior to the start of study treatment)
  • (INR) OR prothrombin time (PT) activated partial thromboplastin time (aPTT) =\< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants (within 10 days prior to the start of study treatment)

Exclusion criteria

Exclusion Criteria:

  • A women of child birth potential () who has a positive urine pregnancy test within 72 hours prior to registration.
  • Has received prior systemic anti-cancer therapy including agents within 4 weeks or 5 half-lives whichever is shorter prior to study entry. Patients may not have received biologics, targeted therapy or immunotherapy for 4 weeks (6 weeks for nitrosoureas or mitomycin C). Hormonal therapy is not considered anti-neoplastic therapy.
  • Has received prior radiotherapy within 3 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require , and not have had radiation pneumonitis. A 2-week is permitted for palliative radiation (=\< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease
  • Has received a within 30 days prior to the first dose of study drug. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug
  • Has a known additional that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
  • Has known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
  • Has severe (>= grade 3) to pembrolizumab, lenvatinib, or paclitaxel and/or any of its . Note, patients with paclitaxel hypersensitivity are eligible if the if infusion can safely be completed with reduced infusion rates and premedication
  • Has active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for hepatitis B and hepatitis C is required unless the patient is at risk for, or has symptoms or signs of, hepatitis
  • Has a known history of active TB (Bacillus Tuberculosis)
  • Known (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with pembrolizumab, lenvatinib and paclitaxel. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
  • Significant cardiovascular disease
  • Major surgical procedure (e.g. laparotomy, bowel resection) 4 weeks prior to start of the study drug.
  • Neuropathy grade > 1
  • Non-healing wound, bone fracture, or skin ulcer
  • Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug
  • Patients who have a history of a small or large bowel obstruction within 2 weeks of screening or who have and active partial small bowel obstruction or percutaneous endoscopic gastrostomy (PEG)-tube
  • Serious/active infection or infection requiring parenteral antibiotics
  • Significant arterial or venous thromboembolic disease or vascular disorders within 6 months prior to administration of first dose of study drug, including by not limited to:

    • Cerebrovascular accident (CVA) or (TIA)
    • Peripheral ischemia > grade 2 (per [CTCAE] version 4.03)
    • Arterial thrombotic event
    • Patients who have a history of deep vein thrombosis or pulmonary embolus \< 3 months prior to enrollment must be excluded. However, if patients are on therapeutic anticoagulation, and the deep vein thrombosis (DVT)/pulmonary embolism (PE) has been clinically stable or improved on anticoagulation for > 3 months, patients are eligible.
    • Patients with a history of clotting disorders must be excluded
  • Significant bleeding disorders within 6 months prior to administration of first dose of study drug
  • Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. Pregnant women are excluded from this study because the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lenvatinib, breastfeeding should be discontinued if the mother is treated lenvatinib. These potential risks may also apply to other agents used in this study
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Treatment (paclitaxel, lenvatinib, pembrolizumab)

    Patients receive paclitaxel IV over 1 hour on days -15 and -8 and lenvatinib PO QD on days -15 to 0. Beginning cycle 1 day 1, patients receive lenvatinib PO QD, pembrolizumab IV over 30 minutes on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles with pembrolizumab repeats every 3 weeks for up to 2 years, and cycles with paclitaxel and lenvatinib repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

    Drug: Lenvatinib · Drug: Paclitaxel · Biological: Pembrolizumab

Interventions

  • Given PO

    Also known as: E7080, ER-203492-00, Multi-Kinase Inhibitor E7080

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • BiologicalPembrolizumab

    Given IV

    Also known as: Keytruda, Lambrolizumab, MK-3475, SCH 900475

06

What researchers measure

Primary outcomes

  1. Objective Tumor Response

    Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Will be reported as a percentage and will be calculated by the number of patients with a complete or partial response divided by the total number of patients. The percentage of patients with stable disease and progressive disease will be calculated in a similar fashion.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Safety and Toxicity

    Toxicity as assessed by Common Terminology for Adverse Events version 5.0 will be evaluated descriptively using frequencies and percentages and will be reported using tables. All patients who receive treatment, regardless of eligibility, will be evaluated for toxicity. Toxicities by type and maximum grade over the course of treatment and follow up will be summarized and by date of occurrence.

    Time frame: through study completion, an average of 1 year

  2. Progression Free Survival

    Time from first therapy to the time of cancer progression, death or lost to follow up.

    Time frame: through study completion, an average of 1 year

07

Results

Posted Oct 21, 2026
Limitations and caveats
This is an investigator initiated study

Participant flow

Safety lead in: dose level 1
Participant flow — Safety lead in: dose level 1
MilestoneSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2 (Dose Level -1)
Started400
Completed400
Not completed000
Safety lead in: dose level -1
Participant flow — Safety lead in: dose level -1
MilestoneSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2 (Dose Level -1)
Started050
Completed050
Not completed000
Phase 2: RP2D
Participant flow — Phase 2: RP2D
MilestoneSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2 (Dose Level -1)
Started0029
Completed0029
Not completed000

Outcome measures

PrimaryObjective Tumor Response

Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Will be reported as a percentage and will be calculated by the number of patients with a complete or partial response divided by the total number of patients. The percentage of patients with stable disease and progressive disease will be calculated in a similar fashion.

Time frame:
through study completion, an average of 1 year
Reported as:
Count of participants · Participants
Objective Tumor Response
ParticipantsSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2 (Dose Level -1)
Complete Response003
Not assessed003
Not evaluable202
Partial Response1212
Progressive Disease002
Stable Disease137
SecondarySafety and Toxicity

Toxicity as assessed by Common Terminology for Adverse Events version 5.0 will be evaluated descriptively using frequencies and percentages and will be reported using tables. All patients who receive treatment, regardless of eligibility, will be evaluated for toxicity. Toxicities by type and maximum grade over the course of treatment and follow up will be summarized and by date of occurrence.

Time frame:
through study completion, an average of 1 year
Reported as:
Number · participants
Safety and Toxicity
participantsSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2: Dose Level -1
Anemia2423
Febrile neutropenia002
Myocardial infarction001
Palpitations003
Sinus tachycardia027
Ear pain002
Tinnitus004
Hyperthyroidism002
Hypothyroidism3416
Blurred vision006
Dry eye113
Eye disorders - other013
Photophobia001
Watering eyes012
Abdominal distension123
Abdominal pain1215
Bloating105
Colitis001
Constipation2212
Eosinophilia001
Aortic valve disease001
Atrial fibrillation001
Atrioventricular block first degree001
Cardiac disorders - Other002
Hearing impaired001
Vertigo001
Cataract001
Glaucoma001
Anal fistula001
Ascites001
Belching001
Diarrhea2323
Dry Mouth3111
Dyspepsia125
Dysphagia112
Fecal incontinence013
Flatulence004
Gastroesophageal reflux disease015
Gastrointestinal disorders - Other003
Hemorrhoids002
Ileus002
Lip pain001
Mucositis oral2420
Nausea3421
Oral dysesthesia002
Oral pain007
Rectal hemorrhage006
Rectal pain003
Small intestinal obstruction001
Vomiting2319
Chills1010
Edema face013
Edema limbs0114
Fatigue4425
Fever005
General disorders and administration site conditions - Other011
Generalized edema101
Infusion site extravasation001
Localized edema012
Malaise001
Non-cardiac chest pain117
Pain003
Bile duct stenosis001
Cholecystitis001
Allergic reaction012
Anorectal infection001
Conjunctivis001
Device related infection002
Enterocolitis infectious002
Folliculitis001
Infections and infestations - Other023
Lung infection005
Mucosal infection001
Nail infection013
Rash pustular102
Sinusitis002
Skin infection001
Thrush002
Tooth infection001
Upper Respiratory Infection104
Urinary tract infection139
Vaginal infection013
Bruising004
Fall205
Fracture001
Infusion related reaction102
Injury, poisoning and procedural complications - Other001
Intestinal stoma site bleeding001
Vascular access complication001
Wound complication011
Activated partial thromboplastine time prolonged016
Alanine aminotransferase increased015
Alkaline phosphatase increased015
Aspartate aminotransferase increased017
Blood bicarbonate decreased001
Blood bilirubin increased003
Blood lactate dehydrogenase increased026
Cardiac troponin I increased003
Cholesterol high001
Creatinine increased114
Electrocardiogram QT corrected interval prolonged012
INR increased001
Lipase increased001
Lymphocyte count decreased1322
Lymphocyte count increased001
Neutrophil count decreased1519
Pancreatic enzymes decreased001
Platelet count decreased0113
Thyroid stimulating hormone increased117
Weight gain015
Weight loss4315
White blood cell decreased1522
Anorexia3420
Dehydration127
Hyperglycemia1517
Hypercalcemia001
Hyperkalemia002
Hypernatremia001
Hyperphosphatemia025
Hypertriglyceridemia012
Hyperuricemia015
Hypoalbuminemia0210
Hypocalcemia026
Hypoglycemia012
Hypokalemia1214
Hypomagnesemia029
Hyponatremia2314
Hypophosphatemia004
Paroxysmal atrial tachycardia110
Hemorrhoidal hemorrhage100
Back pain317
Flank pain101
Myalgia305
Neck pain105
Pain in extremity316
Headache1221
Peripheral sensory neuropathy109
Depression1210
Insomnia118
Dysuria1110
Proteinuria1317
Urinary frequency116
Urinary incontinence113
Urinary retention103
Urinary tract obstruction111
Cough1216
Dyspnea1422
Epistaxis1219
Hoarseness126
Hypoxia115
Nasal congestion1114
Postnasal drip106
Productive cough120
Sore throat1113
Alopecia122
Rash acneiform102
Rash maculo-papular1317
Surgical and medical procedures - Other110
Hypertension1224
Hypotension119
Ear and labyrinth disorders - Other010
Esophageal stenosis010
Esophagitis010
Hypothermia010
Arthralgia015
Dizziness0214
Dysgeusia0210
Extrapyramidal disorder010
Anxiety014
Cystitis noninfective010
Glucosuria012
Hematuria0213
Vaginal discharge012
Vaginal inflammation010
Respiratory, thoracic and mediastinal disorders - Other011
Nail changes017
Palmar-plantar erythrodysesthesia syndrome028
Skin and subcutaneous tissue disorders - Other025
Skin ulceration011
Flushing024
Bone pain002
Generalized muscle weakness006
Joint range of motion decreased001
Muscle cramp008
Muscle weakness lower limb002
Musculoskeletal and connective tissue disorder - Other, specify001
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other001
Concentration impairment001
Edema cerebral001
Memory impairment001
Nervous system disorders - Other001
Peripheral motor neuropathy001
Presyncope001
Stroke001
Syncope002
Tremor003
Vasovagal reaction001
Agitation002
Confusion001
Hallucinations002
Psychiatric disorders - Other001
Restlessness004
Acute kidney injury002
Bladder spasm001
Chronic kidney disease001
Renal and urinary disorders - Other001
Urinary urgency004
Urine discoloration001
Pelvic floor muscle weakness001
Pelvic pain009
Vaginal fistula001
Vaginal hemorrhage002
Vaginal pain002
Allergic rhinitis001
Pharyngeal mucositis001
Pleural effusion002
Pneumonitis002
Rhinorrhea003
Sinus pain001
Voice alteration002
Wheezing001
Dry skin003
Hyperhidrosis002
Nail discoloration001
Pain of skin001
Pruritus007
Hot flashes002
Thromboembolic event005
SecondaryProgression Free Survival

Time from first therapy to the time of cancer progression, death or lost to follow up.

Time frame:
through study completion, an average of 1 year
Reported as:
Median · months
Progression Free Survival
monthsSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2 (Dose Level -1)
Progression Free Survival5.15 (4.20 to NA)7.2 (3.0 to NA)6.80 (3.90 to 15.10)

Adverse events

Collected over Adverse event data was collected through treatment completion plus 90 days, an average of 1 year. All-cause mortality data is collected as part of long-term follow-up until participant death, withdrawal of consent, or until the study closes, with an average follow-up of15.6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Lead in: Dose Level 14/4 (100%)3/4 (75%)4/4 (100%)
Safety Lead in: Dose Level -15/5 (100%)4/5 (80%)5/5 (100%)
Phase 2 (Dose Level -1)22/29 (75.9%)19/29 (65.5%)29/29 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2 (Dose Level -1)
Urinary tract infectionInfections and infestations0/42/51/29
AnemiaBlood and lymphatic system disorders1/40/51/29
FatigueGeneral disorders and administration site conditions1/40/51/29
AnorexiaMetabolism and nutrition disorders1/40/51/29
DehydrationMetabolism and nutrition disorders1/40/51/29
HyponatremiaMetabolism and nutrition disorders1/40/51/29
HypokalemiaMetabolism and nutrition disorders1/40/50/29
Urinary tract obstructionRenal and urinary disorders1/40/50/29
HypoxiaRespiratory, thoracic and mediastinal disorders1/40/50/29
DiarrheaGastrointestinal disorders0/41/53/29
Most frequent other events
Showing 10 of 222
Most frequent other events
EventSafety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2 (Dose Level -1)
FatigueGeneral disorders and administration site conditions4/44/525/29
Neutrophil count decreasedInvestigations1/45/519/29
Weight lossInvestigations4/43/515/29
White blood cell decreasedInvestigations1/45/522/29
HyperglycemiaMetabolism and nutrition disorders1/45/517/29
AnemiaBlood and lymphatic system disorders2/44/523/29
HypothyroidismEndocrine disorders3/44/516/29
Mucositis oralGastrointestinal disorders2/44/520/29
NauseaGastrointestinal disorders3/44/521/29
AnorexiaMetabolism and nutrition disorders3/44/520/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)Safety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2Total
Median59 (45 to 68)65 (64 to 78)63 (37 to 78)64.5 (37 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Safety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2Total
Female452938
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Safety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2Total
Hispanic or Latino1012
Not Hispanic or Latino352836
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2Total
American Indian or Alaska Native0000
Asian0022
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White252532
More than one race2013
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Safety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2Total
United States452938
Primary site of cancer
Primary site of cancer(Participants)Safety Lead in: Dose Level 1Safety Lead in: Dose Level -1Phase 2Total
Ovarian Cancer332026
Endometrial Cancer12912
08

Study locations

2 sites
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jul 2025, 46 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's 46 months is below that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Mar 2027, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Mar 4, 2021
StartActual
Sep 1, 2021
Primary completionActual
Jul 1, 2025
CompletionEst.
Mar 15, 2027was Aug 2026
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Study completion
Aug 31, 2026→Mar 15, 2027
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedObjective tumor responseTumor ResponseTime frame: through study completion, an average of 1 year
Oct 21, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedProgression free survivalFree SurvivalTime frame: through study completion, an average of 1 year
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Study completion Aug 31, 2026→Mar 15, 2027
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedObjective tumor responseTumor ResponseTime frame: through study completion, an average of 1 year
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression free survivalFree SurvivalTime frame: through study completion, an average of 1 year
    + 4 other changes: index terms, verification date, responsible party and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04781088
Lead sponsor
Floor Backes, MD
Responsible party
Floor Backes, MD (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Mar 4, 2021
Start date
Sep 1, 2021
Primary completion
Jul 1, 2025
Completion
Mar 15, 2027 (estimated)
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Floor Backes, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Paclitaxel · Pembrolizumab

Start the discussion